恩華藥業(002262.SZ)獲鹽酸戊乙奎醚注射液3個規格的藥品註冊批件
格隆匯1月14日丨恩華藥業(002262.SZ)公佈,公司於近日獲得國家藥品監督管理局核准簽發的化學藥品鹽酸戊乙奎醚注射液3個規格的《藥品註冊批件》,規格分別為1ml:1mg;1ml:0.5mg;2ml:2mg。
鹽酸戊乙奎醚注射液為選擇性抗膽鹼藥,可用於麻醉前給藥以抑制唾液腺和氣道腺體分泌,以及有機磷毒物(農藥)中毒急救治療和中毒後期或膽鹼酯酶(ChE)老化後維持阿托品化。該產品已被列入《國家醫保目錄》(2019版)乙類藥品、《國家基本藥物目錄》(2018版)。
此次獲得鹽酸戊乙奎醚注射液3個規格的《藥品註冊批件》,豐富了公司在麻醉領域的產品管線,有利於提升公司的市場競爭力,其上市銷售將對公司今後業績的提升產生積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.